Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$792.52 USD

792.52
2,561,839

+16.14 (2.08%)

Updated Nov 7, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

The Zacks Analyst Blog Highlights: Exxon Mobil, Eli Lilly, Costco, Aon and EOG Resources

The Zacks Analyst Blog Highlights: Exxon Mobil, Eli Lilly, Costco, Aon and EOG Resources

Sheraz Mian headshot

Top Stock Reports for Exxon Mobil, Eli Lilly & Costco

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Eli Lilly (LLY), and Costco Wholesale (COST).

AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA

The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.

Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA

The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

Style Box ETF report for FLQL

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall

Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.

Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline

Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.

Lilly (LLY) Stock Riding on Pipeline Developments This Year

Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.

Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant

Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.

Kinjel Shah headshot

Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

SNY vs. LLY: Which Stock Is the Better Value Option?

SNY vs. LLY: Which Stock Is the Better Value Option?

WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara

The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.

Lilly's (LLY) Jardiance Heart Failure Study Meets Main Goal

Lilly's (LLY) Jardiance significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction.

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer

Kinjel Shah headshot

3 Big Drugmakers Likely to be in Focus in Second Half of 2021

Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.

The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group

The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group

Mark Vickery headshot

Top Analyst Reports for Alphabet, Visa & Eli Lilly

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Visa (V), and Eli Lilly (LLY).

Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status

Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.

Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19

The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.

AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Kidney Disease

The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of chronic kidney disease in adults with and without type-II diabetes.

AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA

The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults.

Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status

Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.

Entera (ENTX) Up on Positive Results From Osteoporosis Drug

Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data

EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.